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Rare Haematological Malignant 
Diseases after Allogeneic 
Haematopoietic Stem Cell 
Transplantation
Eva Hanusovska and Sabina Sufliarska
Abstract
Allogeneic haematopoietic stem cell transplantation (allo-hSCT) is one of the 
most important therapeutic options for patients with both malignant and non-
malignant life-threatening rare disorders. Assessment of chimerism following 
allo-hSCT has been established as an indispensable tool for the clinical manage-
ment of transplant recipients. The number of allo-hSCT among CML patients 
is decreasing due to tyrosine-kinase-inhibitor treatment. However, allo-hSCT 
in adult and paediatric patients with AML, ALL, and different non-malignant 
diseases is still increasing. For sex-independent patient chimerism monitoring, 
PCR-based short tandem repeat (PCR-STR) DNA markers with subsequent frag-
ment analysis (‘FA’) and SYBR Green-based real-time PCR (SNPs or NPs markers 
of DNA) (‘RQ PCR’) were used. Specific features of chimerism assessment in 
non-malignant (n = 74) and malignant (n = 169) diseases were monitored by ‘FA’. 
Complete and mixed chimerism was monitored also by SYBR Green-based real-
time PCR method (‘RQ PCR’) (n = 188). By comparing the results of two chime-
rism monitoring methods (‘FA’ and ‘RQ PCR’) (n = 65), the higher sensitivity for 
the detection of the autologous DNA markers was observed by ‘RQ PCR’ (<1%) 
than ‘FA’ (1–5%). The lower detection limit of mixed chimerism could reveal an 
eventual relapse earlier. But the quantification of donor’s DNA markers is more 
precise estimated by the FA.
Keywords: allo-hSCT, chimerism monitoring, diallelic indel polymorphisms,  
PCR-STR, rare diseases
1. Introduction
Bone marrow transplantation is widely used for many different kinds of hae-
matological malignancies such as leukaemias/lymphomas and immunodeficiency 
which are rare diseases. Over the past decades, allogeneic haematopoietic stem 
cell transplantation (allo-hSCT) has gained increasing importance as a treatment 
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option for patients with both malignant and non-malignant life-threatening 
disorders in adult as well as paediatric patients. High risk leukaemias that are indi-
cated for allo-hSCT are acute myeloid leukaemia (AML) [1], acute lymphoblastic 
leukaemia (ALL) and chronic myeloid leukaemia (CML) resistant to tyrosine-
kinase inhibitor targeted treatment [2]. Also, myelodysplastic syndrome (MDS) 
and many other non-malignant disorders (bone marrow failure syndromes, 
haemoglobinopathies, immunodeficiencies and osteopetrosis) can profit from 
allo-hSCT [3].
Considerable progress has been made in the analysis of haematopoietic chi-
merism afterwards, and the molecular monitoring of the genotypic origin of 
engrafted cells has become a routine diagnostic tool to document engraftment 
and to detect graft rejection or impending relapse, at most centres performing 
allogeneic hSCT [4]. The term ‘chimerism’ was introduced in the field of medi-
cine by Anderson et al. [5] to describe organisms whose cells derive from two or 
more zygote lineages. Close surveillance of chimerism within total peripheral 
blood leukocytes after an allogeneic hSCT seems an indispensable tool for the 
clinical management of transplant recipients [6]. In order to identify donor cells 
and even small amounts of residual host cells, many genetic methods have been 
established for this purpose. Cytogenetics and fluorescence in situ hybridization 
(FISH) analysis are the older ones and are applicable only in sex-mismatched 
transplantations where the proportion of X and Y chromosomes are detected [7]. 
The variability between individuals can be found both on the phenotype and on the 
genotype levels, especially in non-coding areas of the DNA. The later can be used 
not only in the population genetics, evolutionary studies and forensic and paternity 
proofs but also in the medicine as appropriate DNA informative markers to identify 
the donor and the recipient (host; patient) on the molecular level and monitor 
chimerism after allo-hSCT. For sex-independent patient chimerism monitoring, 
the PCR-based analyses of highly polymorphic short tandem repeats (STR; PCR-
STR) DNA markers with subsequent fragment analysis (‘FA’) on Genetic Analyser 
are frequently used [8, 9]. Single-nucleotide polymorphism (SNP) or nucleotide 
polymorphisms (NPs) assessment by relative quantification SYBR Green-based 
real-time PCR, (‘RQ PCR’) Real-time PCR and semi-nested real-time PCR are used 
less [10–12], but due to increased interest in diallelic insertion/deletion polymor-
phisms ‘DIPs’ [13, 14], many new commercially kits for chimerism monitoring are 
available. In spite of the different analytical approaches to detect post-transplant 
chimerism, it seems to be useful to explain some common features. The term 
‘complete chimerism’ (CC) expresses the status, where only the donor genotype is 
detected in the patient blood sample after allo-hSCT by the certain method. The 
term ‘mixed chimerism’ (MC) expresses the status, where both donor and recipi-
ent (host) genotypes are detected in the patient blood sample after allo-hSCT by 
the certain method. However, the post-transplant chimerism is a dynamic process. 
Several days, weeks, or months after allo-hSCT, the mixed chimerism is usually 
slowly changed to complete donor chimerism named ‘decreasing mixed chimerism’. 
Vice versa in the case of a relapse when autologous haematopoiesis is appeared 
often the complete chimerism becomes to the status of mixed chimerism named 
‘increasing chimerism’. The coexistence of donor and recipient haematopoiesis for 
months or a longer period (especially in non-malignant disorders) is named ‘stable 
mixed chimerism’ [3].
In following chapters, we would like to describe not only two different DNA 
molecular methods (‘FA’ and ‘RQ PCR’), which have been used in chimerism 
monitoring after allo-hSCT in our laboratories, but also its comparison from our 
results.
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2. PCR-STR DNA markers in chimerism monitoring by ‘FA’
2.1 Introduction
Quantitative monitoring of chimerism after allo-hSCT based on PCR 
amplification of microsatellite STR markers has become an important compo-
nent of post-transplant surveillance of patients. Each STR marker is a system 
of many alleles, all sharing the basic structure of a repeat (2–8 bp in length), 
(4–5 bp in our study) but differing in the number of tandem repeats of this 
sequence. They can be applied for follow-up of virtually all patients and only 
small amounts of DNA are required for the test to estimate to donor/recipi-
ent chimerism after allo-hSCT [15–17]. Quantitative chimerism monitoring 
can document engraftment, predict graft failure or rejection, identify those 
patients who are at the highest risk to develop relapse and clarify the origin of 
the cells after relapse [18–23].
2.2 Methods
The PCR-based STR (PCR-STR) DNA markers were amplified using fluores-
cently labelled allele-specific primers, and different amplicons were separated by 
capillary electrophoresis on Genetic analyser. The direct quantification of donor 
and recipient PCR-STR DNA markers was provided by fragment analysis (FA) of 
GeneMapper software (Applied Biosystems) [20, 24–28].
2.3 Sample collection
Whole peripheral blood samples were collected for DNA extraction from both 
the donor and recipient before transplantation in order to determine an informative 
STR marker. The samples were collected at weekly or monthly intervals during the 
first 100 days, and monthly or every 2–3 months thereafter during the first year 
according to the transplantation centre. During the second year, the frequency 
was reduced to twice a year, only if the clinical situation warranted, more frequent 
chimerism analyses were performed.
2.4 DNA extraction
Genomic DNA was extracted from 200 μl of fresh or frozen peripheral blood 
using a column-based DNA isolation technique (Qiagene DNA Blood mini kit, 
QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. DNA 
quantification was performed using standard UV absorption at 260 nm, and DNA 
samples were stored until use at −80°C. To obtain an informative STR system for 
chimerism analysis, we performed a donor/recipient genotyping using a commer-
cially available STR multiplex amplification kit PowerPlex 16 (Promega, Madison, 
WI, USA) that contains tetranucleotide STR markers, e.g. D18S51, D21S11, TH01 
and D3S1358, as well as pentanucleotide STRs Penta E and Penta D and the primers 
specific for the Amelogenin locus [27, 28].
2.5 PCR amplification
About 10–50 ng of genomic DNA and BioThermStar DNA polymerase 
(GeneCraft, Lüdinghausen, Germany) instead of AmpliTaq Gold DNA polymerase 
(Applied Biosystems, Foster City, CA, USA) in some reactions. The denaturation, 
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annealing and extension cycles were programmed in Techgene thermal cycler 
(Techne Inc., Burlington, NJ, USA) as follows: preincubation 95°C for 10 min, 96°C 
for 1 min, 10 cycles with 96°C/30 s, 60°C/30 s, 70°C/45 s and 14 and 18 cycles with 
96°C/30 s, 60°C/30 s, 70°C/45 s for monoplex and multiplex kits, respectively, and 
final elongation step performed at 60°C for 30 min.
2.6 Fragment analysis
For fragment analysis, a mixture of 1 μl of the PCR product with 8.5 μl deion-
ised formamide and 0.5 μl of the size standard ILS 600 (Promega, Madison, 
WI, USA) was prepared and was subjected to capillary electrophoresis in an ABI 
Prism 3100-Avant Genetic Analyser (Applied Biosystems, Foster City, CA, USA). 
The injection times varied between 4 and 36 s. Fragment length and fluorescence 
intensity were analysed using GeneMapper Software (Applied Biosystems, 
Foster City, CA, USA), and the detection threshold was set for 50 RFU. The 
selection of informative STR loci was based on previously described experiences 
[29, 30], where in such loci donor and recipient alleles should be individually 
distinguishable [15, 18].
2.7 Chimerism in adult malignant disease following hSCT monitored by ‘FA’
2.7.1 Cohort
The cohort consisted of 169 adult and paediatric malignant patients from three 
Slovak bone marrow transplantation centres who underwent allo-hSCT between 
the years 1993 and 2010, and chimerism analysis of polymorphic STR markers was 
performed by ‘FA’. A prospective evaluation of chimerism was performed in 171 
patients transplanted after the year 2003 also by ‘FA’ from fresh or frozen DNA 
samples which were available.
2.7.2 Methods
The method included PCR-based analysis (with fluorescent allele specific 
primers) of short tandem repeats (PCR-STR) markers by fragment analysis (‘FA’) 
following capillary electrophoresis in Genetic analyser.
2.7.3 Results
The chimerism analysis of transplant patients was done for the first time no later 
than 1 month after allo-hSCT and further on 1–4 weekly intervals up to day +200 
after transplantation and then according to the chimerism result and the timing of 
clinical controls. Patients who showed no evidence of autologous (recipient) DNA 
at any time in the post-transplantation follow-up were considered to have complete 
chimerism (CC). Patients with both donor and recipient DNA in any of the samples 
analysed were defined as having mixed chimerism (MC). An example of patient’s 
mixed chimerism is presented in Figure 1. The average quantity of donor alleles 
30.2 and 31.2 is 77%. The average quantity of recipient’s alleles 16 and 25.2 is 23%, 
which means patient’s mixed chimerism is 23% (MC = 23%). Patients who showed 
an increase (5% or more) in the proportion of recipient DNA or who changed from 
CC to any level of MC between two consecutive assessments were referred as having 
increasing MC. Those patients with decreasing recipient DNA content (5% or 
more) or transforming from MC to CC in two successive samples were categorised 
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as having decreasing MC [26, 31]. Patients from our cohort with CC, stable MC, 
and decreasing MC showed a significantly better (p = 0.005) overall survival rate 
(OSR = 0.83) after allo-hSCT (Figure 2), compared to those with increasing MC 
(OSR = 0.25) after allo-hSCT (Figure 3) detected at any time after allo-hSCT.
2.7.4 Conclusion
Our observation shows that chimerism analysis gives clear information about 
engraftment, its failure, or graft rejection but is not a sufficiently sensitive method 
to detect an imminent relapse in acute lymphoblastic leukaemia patients. According 
to the changes in chimerism status after transplantation, early implementation of 
immunotherapeutic measures such as rapid cessation of immunosuppression and 
donor lymphocyte infusion (DLI) with or without cytokine coadministration can 
be delivered as prophylaxis and seems to be highly efficacious in restoring CC and 
decreasing autologous cell contents [18, 27, 32].
Figure 1. 
Mixed chimerism (MC) in a patient after allo-hSCT
Figure 2. 
Kaplan-Meier analysis of overall survival in patients with complete chimerism (CC), decreasing, stable mixed 
chimerism (MC) after allo-hSCT.
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2.8  Specific features of chimerism assessment in non-malignant diseases 
monitored by ‘FA’
2.8.1 Introduction
Allo-hSCT is a well-established treatment not only for high risk leukaemias 
and myelodysplastic syndrome (MDS) but also for several non-malignant dis-
eases, including acquired and inherited bone marrow failure (BMF) syndromes 
like aplastic anaemia (AA) and Fanconi anaemia (FA), immunodeficiencies like 
severe combined immunodeficiency (SCID), Wiskott–Aldrich syndrome (WAS), 
chronic granulomatous disease (CGD), haemoglobinopathies and metabolic 
disorders, mostly transplanted in childhood. The aim of transplantation in these 
diseases is to achieve sustained engraftment of donor stem cells to improve 
haematopoietic function, provide immune competence and increase or normalise 
enzyme deficiency. It can completely transform the lives of children for whom life 
expectancy or quality of life would otherwise be very poor. Although complete 
donor haematopoiesis is a desirable outcome of SCT in malignant disorders, 
complete replacement of recipient’s haematopoietic system is not considered 
necessary to improve the underlying disease state in patients with non-malignant 
disorders [33, 34].
2.8.2 Cohort
The cohort consisted of 74 different adult and paediatric non-malignant 
patients from three Slovak bone marrow transplantation centres who underwent 
allo-hSCT.
2.8.3 Methods
The method included PCR-based analysis (with fluorescent allele specific 
primers) of short tandem repeats (PCR-STR) markers by fragment analysis (‘FA’) 
following capillary electrophoresis in Genetic analyser. Surveillance of chimerism 
was done within total peripheral blood leukocytes or as lineage-specific chimerism 
in selected T cells, B cells and myeloid cells after an allogeneic SCT according to 
Park et al. and Thiede [35, 36].
Figure 3. 
Kaplan-Meier analysis of overall survival in patients with increasing mixed chimerism (MC) after allo-hSCT
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2.8.4 Results
Definition of chimerism, as it is described above considers a patient to have 
CC, when he does not show any evidence or less than 1% of autologous—recipient 
DNA at any time after allo-hSCT. Patients with both donor and recipient DNA 
(that increased 5% or more) in any of the samples analysed were defined as having 
MC. Split chimerism is present if one or more leukocyte lineages are of host and one 
or more leukocyte lineages are of donor origin [4, 36, 37].
As other studies mentioned above, also our results show there is a relationship 
between chimerism status and clinical course as well as outcome of allogeneic SCT 
in non-malignant diseases. From our cohort, 75% (55 patients) reached complete 
chimerism (CC) monitored by ‘FA’ and 25% (19 patients) mixed chimerism on 
different levels. Most of the patients with CC and decreasing or stable MC are alive 
doing well and are in remission, with a median follow-up time of 4.3 years. All 
of the patients with high MC (>40% or increasing MC) experienced transplant 
rejections and almost half of them died. Patients with CC had a higher risk of acute 
graft-versus host disease GVHD compared with MC patients.
2.8.5 Conclusion
Therefore, mixed chimerism (if there are still low levels of recipient cells) may 
be welcomed in these patients, as it reflects a decreased allo-response with less 
acute GVHD. Reduced intensity conditioning (RIC) was more often associated with 
decreasing or low stable MC compared to myeloablative conditioning, but impor-
tantly high MC was not different when using reduced intensity conditioning than 
with myeloablative  conditioning [33, 34].
3. SNP and NP DNA markers in chimerism monitoring by ‘RQ PCR’
3.1 Introduction
Chimerism monitoring allows the characterisation of the haematopoietic stem cell 
origin in the recipient’s blood or bone marrow after allo-hSCT. The DNA identifica-
tion of the person is mainly based on the DNA polymorphisms, which include single-
nucleotide polymorphisms (SNPs) due to nucleotide substitutions and insertion or 
deletion of one or more nucleotides (indels). The late can be multiallelic (STR) and 
diallelic (biallelic). The extensive bibliographical search for human diallelic indels 
and its basic properties were determined and selected for chimerism monitoring 
[13, 38]. The sensitive quantitative real-time PCR analysis using indel polymorphisms 
can be the useful tool to predict relapse in leukaemia patients after allo-hSCT [39].
3.2  Complete and mixed chimerism monitoring by SYBR green-based real-time 
PCR method (‘RQ PCR’)
Tens of biallelic (diallelic) nucleotide polymorphisms specific for the donor and 
the recipient can be detected by the method of allele-specific real-time PCR.
3.2.1 Cohort
The cohort consisted of 188 patients from University Hospital Bratislava, 
Slovak Republic and 188 donors (111 from relatives and 77 from national and world 
registers of the bone marrow).
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3.2.2 Methods
The DNA was isolated (NucleoSpin Blood, Macherey-Nagel) from peripheral 
blood leukocytes (centrifugation 3000 × g/10 min) before allo-hSCT from both 
donor and recipient and 30, 100, 180 and 365 days after allo-hSCT only from 
recipient (patient). Concentration of the DNA was measured on NanoPhotometer, 
Implen and samples were diluted to 10 ng/μl. To get allogenic and autologic 
informative markers for quantification after allo-hSCT, screening of donor and 
recipient DNA samples before allo-hSCT was essential. Three 1 μM allele-specific 
primers (two forward and one reverse or one forward and two reverse) for 11 
biallelic nucleotide polymorphic markers were localised on 1st, 5th, 6th, 9th, 11th, 
17th, 18th, 20th and X chromosome. Also, two pairs of specific primers (forward 
and reverse) for monoallelic DNA marker on Y chromosome (amelogenin) and 
for endogenic control gene GAPDH were used (Figure 4) [40]. The amounts for 
one-well allele-specific PCR reaction on 96-well plate were: 12.5 μl Power SYBR 
Green (PCR Master mix, Power SYBR green; Applied Biosystems), 1.25 μl 1 μM 
forward-primer (A or B) and1.25 μl 1 μM reverse primer (C) or vice versa (Sigma 
Genosys), 5 μl DNA (10 ng/ul), 5 μl DNase, RNase free water to final volume 25 μl. 
Thermal profile of 7300 Real Time PCR System (Applied Biosystems) for allele-
specific PCR: 50°C/2 min, 1×; 95°C/10 min, 1×; (95°C/0.15 min, 60°C/1 min)/50×; 
and dissociation of amplicons with incorporated SYBR green: 94°C/0.15 min; 
60°C/0.30 min; increasing 1°C/min; 95°C/0.15 min. Amplification curves from 
real-time PCR with following dissociation curves revealed type A, or B of marker 
(M) allele (MA or MB). For each donor/recipient pair, there are different infor-
mative markers for relative quantification and chimerism estimation after allo-
hSCT. Relative quantification was calculated and evaluated from amplification 
plots of the individual PCR reactions on 96-well plate by the gene expression Study 
software (7300 System SDS Software, Applied Biosystems). Amplification plot 
of each informative marker before alloTKB was used as the calibrator for relative 
quantification of measured marker and amplification plot of gene GADPH was 
used as endogenous control [40].
3.2.3 Results
In most of screened donor/recipient pairs, we have found 2–3 informative 
autologous and allogeneic markers. An example of donor and recipient (patient) 
screening for informative NPs DNA markers (M1–M12) by SYBR green-based 
real-time PCR amplification and following dissociation curves is presented in 
Figure 5. For this donor/recipient pair, recipient’s marker 3B (M3B) can be con-
sidered as informative autologous marker and can be used for chimerism monitor-
ing after allo-hSCT. Only in three cases, we did not find any of the informative 
autological DNA markers, which are most convenient (detection <1%) for the 
measurement of micro chimerism. After allo-hSCT, informative DNA markers 
found in samples of patient’s peripheral blood of patients were quantified. The 
relative amounts (expressed in %) were evaluated from threshold cycle (cT) 
values of amplification curves and analysed by Study Software, previously used 
for a relative quantification of the gene expression. The results of the DNA marker 
quantification measurements were obtained from (relative quantification) RQ 
and simultaneously from the charts, which had been constructed automatically 
[41] and transformed (Figure 6). In this figure, chimerism monitoring of AML 
patient after allo-hSCT is expressed. All patients were regularly monitored, and 
from the quantification of autologous informative DNA markers, mixed (MC) or 
9Monitoring of Chimerism in Rare Haematological Malignant Diseases after Allogeneic…
DOI: http://dx.doi.org/10.5772/intechopen.89845
complete (CC) chimerism was evaluated. Identification of donor allogenous infor-
mative markers have evaluated only semiquantitatively. Cutoff for CC was 0.01% 
with relative quantification sensitivity RQ = 0.0001. Special time-dependent 
charts for each patient were archived and sent to doctors in appropriate transplan-
tation units.
3.2.4 Conclusion
We have implemented the method of DNA diagnostics for the detection of 
micro chimerism (add to cytogenetics and FISH previously used) after allo-hSCT, 
which is independent from the sex of donor and recipient and reaches sensitivity of 
<1% (0.01%). The method of relative quantification by real-time PCR is currently 
routinely used in our clinical practice and can serve clinician as another factor for 
the patients monitoring after haematopoietic stem cell transplantation and his early 
intervention if necessary.
Figure 5. 
An example of screening DNA markers M1-M12 by SYBR green based real-time amplification and following 
dissociation curves. Recipient’s marker 3B can be used for chimerism monitoring after allo-hSCT.
Figure 4. 
Localisation of DNA markers (M1-M12) (11NPs).
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3.3  Different malignant and non-malignant diagnosis in our study and their 
donors provided by ‘RQ PCR’
3.3.1 Results
In our diagnostic laboratory, we have analysed samples from patients before and 
after allo-hSCT with different malignant and non-malignant diagnoses (Figure 7).
During the last decades, the number of allo-hSCT among CML patients is 
decreasing due to the drug-targeted treatment and transplantation is mostly 
indicated in the case of resistance to targeted tyrosine-kinase-inhibitor treatment. 
In our study, only 9 CML patients were transplanted from the cohort of 188 dif-
ferent malignant and non-malignant diagnosis (patients from University Hospital 
Bratislava, Slovak Republic), which is only 5%. The majority of allo-hSCT were 
provided and chimerism was monitored in AML patients (45%); then, ALL patients 
were 31% and MDS with others non-malignant diagnoses were 19% (11 + 8).
The selection of a donor is a critical element contributing to the success of 
haematopoietic cell transplantation. Possible donors for allo-hSCT can be HLA 
identical, haploidentical or mismatched (sibling, relative or unrelated donor). In 
our study, there were 188 donors (111 from relatives and 77 from Slovak National 
Bone Marrow Donor Registry and world registers of the bone marrow donors) and 
188 recipients (Table 1). About 95% haemopoietic stem cells were obtained from 
peripheral blood by its drug mobilisation. Only 5% stem cells were from the bone 
marrow.
3.3.2 Conclusion
From our results, it is obvious that assessment of sex-independent donor/recipi-
ent method based on SYBR green real-time relative quantification RQ PCR) for 
chimerism monitoring has been very important due to cohort of different gender 
donor/recipient pairs. This molecular method has completed cytogenetics and 
FISH methods used previously for chimerism monitoring. The advantage of ‘RQ 
PCR’ compared to methods mentioned above is not only in its higher diagnostic 
and analytical sensitivity and sex-independent monitoring but also in the fact 
Figure 6. 
Chimerism monitoring of AML patient after allo-hSCT by SYBR green based real-time PCR relative 
quantification method. MC, mixed chimerism; CC, complete chimerism.
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that almost 50% of AML patients has not genetic mutation marker to distinguish 
increasing mix chimerism and no indicator for relapse of primary patient disorder 
before allo-hSCT.
4.  Chimerism evaluation by two different DNA marker sets and 
molecular methods ‘FA’ and ‘RQ PCR’
4.1 Introduction
The aim of our study was to compare patient’s chimerism monitoring by two dif-
ferent DNA marker type sets and molecular methods ‘FA’ and ‘RQ PCR’ measured in 
parallel after allo-hSCT [40, 42]. The subject matter of the first PCR-STR method 
‘FA’ is explained in chapter ‘2—PCR-STR DNA markers in chimerism monitoring 
by “FA”’. Informative STR DNA markers were amplified with special fluorescent 
Figure 7. 
Different malignant and non-malignant diagnosis in process of allo-hSCT
Types of recipient/donor in allo-hSCT
Total number of transplant patients-recipients 188
Total number of donors 188
Related donors for allo-hSCT 111
Female/female 15
Male/male 42
Sex-mixed 54
Unrelated donors (MUD) for allo-hSCT 77
Female/female 9
Male/male 33
Sex-mixed 35
Table 1. 
Types of recipient(patient)/donor variants in the process of allo-hSCT.
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labelled primers by PCR. Amplicons were separated by the capillary electrophoresis 
on genetic analyser and then evaluated by fragment analyses GeneMapper software. 
The basis of the second method ‘RQ PCR’ (SYBR green-based relative quantifica-
tion by real-time PCR) to be compared is discussed in the chapter “3—SNP and NPs 
DNA markers in chimerism monitoring by RQ PCR”. Informative SNP and biallelic 
NP (including DIPs—IN/DEL polymorphic markers) DNA markers were obtained 
from donor’s and recipient’s DNA before transplantation by SYBR green-based 
real-time PCR amplification following dissociation curves analysing screening. Post 
allo-hSCT chimerism monitoring is provided by relative quantification (RQ-PCR) 
of SYBR green-based real-time PCR of SNP or NPs informative DNA markers and 
evaluated by gene expression software. The relative quantity of the donor’s and 
recipient’s DNA markers is proportional to total leukocytes and can be expressed as 
mixed (MC) or complete chimerism (CC) in post-transplant patients.
4.2 Cohort
The cohort consisted of 65 AML, ALL and CML patients from Department of 
Haematology and Transfusion, Comenius University Medical School Bratislava and 
65 donors from national and international bone marrow registers according their 
HLA compatibility to the individual patient.
4.3 Methods
Whole peripheral blood samples were collected for DNA extraction from both 
the donor and recipient before transplantation in order to determine an informa-
tive marker for two molecular methods mentioned previously. The blood samples 
of leukaemia patients (AML, ALL and CML) after allo-hSCT (N = 65 pairs) were 
collected at regular time periods (before allo-hSCT and 30 days, 100 days, 6-month, 
1 year, 2 years and 3 years after allo-hSCT) at the Department of Haematology and 
Transfusion, Comenius University Medical School Bratislava. Isolation of the DNA 
and chimerism testing was provided in two diagnostic laboratories: Laboratory 
Diagnostics Medirex, Bratislava and Bone Marrow Transplantation Unit, Bratislava, 
Slovak republic, EU. RQ-PCR was performed by the real-time PCR system using 
SYBR green and 12 pairs of specific primers for two allelic variants of DNA poly-
morphism and GAPDH as endogenous gene control. The cT (threshold cycle) 
values of informative patient’s DNA markers before allo-hSCT were used as calibra-
tor for the relative quantification. The PCR reaction mixtures and DNA were placed 
on 96-well reaction plates in duplicates separately, not as multiplex amplification 
set. Relative quantification was evaluated by gene expression software study [40]. 
The PCR-STR analysis was performed using commercially available STR multiplex 
amplification kits with fluorescently labelled PCR primers. The quantification of 
donor and recipient DNA marker’s signal was provided by comparing the fluores-
cence intensity given by the peak area of analysed fragments [20].
4.4 Results
We screened 65 related and unrelated donor/recipient pairs by both molecu-
lar methods, and we found at least one informative marker for each laboratory 
approach mentioned above. The parallel quantifications of DNA (two different 
informative DNA marker sets used) were provided by both methods, and the 
estimated chimerism was compared at the same time period after the allogeneic 
haematopoietic stem cell transplantation. We found that our results were identical 
only in 2% and the discrepancy was noticed also in 2% between the two methods 
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used. In the case of 1–50% mixed chimerism (MC), similar results were obtained. 
However, complete chimerism (CC) estimated by the fragment analysis was evalu-
ated as mixed chimerism (MC) by the real-time PCR in 94% patients, mainly in 
the first half of a year of the post-transplantation monitoring. The example of the 
parallel monitoring of one patient is shown in Figure 8. From this presented results 
of patient chimerism monitoring, we can see that 30 days after allo-hSCT mixed 
chimerism was detected by both methods used (FA-MC and RQ PCR-MC). Also 1, 
2 and 3 years after allo-hSCT, both methods showed identical complete chimerism 
results (FA-CC and RQ PCR-CC). But the discrepancy was revealed 100 days after 
allo-hSCT where complete chimerism was detected by the method FA (FA-CC), but 
simultaneously mixed chimerism was detected by RQ PCR method (RQ PCR-MC) 
in the same patient sample.
4.5 Conclusion
The parallel chimerism monitoring of post allo-hSCT leukaemia patients was 
provided for 3 years. Discrepancy between complete chimerism (CC) detected by 
the fragment analysis (FA) of PCR-STR DNA markers and mixed chimerism (MC) 
detected by the real-time PCR of SNP and NP DNA markers was due to the different 
sensitivity of two methods used. It is also important to note that in different molec-
ular diagnostic approaches also, two different DNA marker sets were used. RQ PCR 
had the higher sensitivity (<1%) for the detection of the autologous DNA markers 
than FA (1–5%), so it is better for earlier revealing of eventual relapse. On the other 
hand, the quantification of donor’s DNA markers is more precise estimated by the 
FA. Both methods compared above are suitable for chimerism assessment after 
Figure 8. 
Parallel monitoring of chimerism of one leukaemia patient after haematopoietic allogeneic stem cell 
transplantation (allo-hSCT) by two DNA molecular methods in different time periods. FA, analysis of PCR-
STR DNA markers by fragment analysis following capillary electrophoresis on Genetic analyser; RQ-PCR, 
analysis of SNP and NPs DNA markers by relative quantification of SYBR green-based Real-time PCR; 
CC, complete chimerism (only donor’s DNA markers detected in patient); MC, mixed chimerism (recipient’s 
-autologous and donor’s DNA markers detected in patient). 100 days after allo-SCT complete chimerism was 
detected by the method FA (FA-CC), but simultaneously mixed chimerism was detected by RQ PCR method 
(RQ PCR-MC) due to its different sensitivity.
Rare Diseases
14
the allogeneic haematopoietic stem cell transplantation, although nowadays many 
new kits with different DNA marker sets (STR, SNP, NPs and DIPs) for chimerism 
monitoring are available.
5. Conclusions
A number of studies have shown that chimerism evaluation based on PCR 
amplification of polymorphic microsatellite STR markers is a readily applicable 
technique, informative almost for all patients, but less sensitive then real-time PCR 
of SNP and NPs DNA method. It is important to notice that complete, mixed chime-
rism, decreasing chimerism, and increasing chimerism are only the relative terms, 
because different laboratories have their own criteria to differentiate between 
complete donor chimerism and mixed decreasing chimerism, based on the method 
that is used, its sensitivity and local policies [43–45]. However, both provide a 
powerful tool in post-transplant decision making. They can document engraftment, 
predict graft failure or rejection, identify those patients who are at the highest 
risk to develop relapse and clarify the origin of the cells after relapse. According 
to the changes in chimerism status after transplantation, early implementation of 
immunotherapeutic measures such as rapid cessation of immunosuppression and 
donor lymphocyte infusion (DLI) with or without cytokine coadministration can 
be delivered as prophylaxis and seems to be highly efficacious in restoring CC and 
decreasing autologous cell contents.
We appreciate the huge Human Genomic Project, because we can use its results 
also in our small labs and participate on the patient quality of life improvement by 
chimerism monitoring after allogeneic haematopoietic stem cell transplantation.
Acknowledgements
We thank our parents Milada with Alexander and Valeria with Julius for their 
example of a life fulfilled with enthusiasm dedicated to the research.
Conflict of interest
The authors declare no conflict of interest.
Abbreviations
ALL acute lymphoblastic leukaemia
AML acute myeloid leukaemia
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